Loading clinical trials...
Loading clinical trials...
A Phase 1b Study of WU-NK-101 in Combination With Cetuximab for Advanced and/or Metastatic Colorectal Cancer (CRC) and Advanced and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Conditions
Interventions
WU-NK-101 - Dose Escalation
Cetuximab - Dose Escalation
+2 more
Locations
2
United States
UCSF
San Francisco, California, United States
Montefiore Medical Center
The Bronx, New York, United States
Start Date
May 21, 2024
Primary Completion Date
September 30, 2025
Completion Date
June 1, 2026
Last Updated
April 15, 2025
NCT04895709
NCT05952934
NCT06634875
NCT06385080
NCT06487403
NCT06242470
Lead Sponsor
Wugen, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions